secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001104659-24-031918
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024
--------------------------------------------------------------------------------

- Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.
- GAAP gross margin 45%; adjusted gross margin 58%; net loss $37.7M vs $32.9M.
- Adjusted EBITDA loss improved to $14.6M from $22.9M.
- Cash $19.3M as of Dec 31, 2023; proceeds $14.6M from orthobiologics divestiture.
- FDA 510(k) decision for CanGarooRM expected in first half 2024; no additional data requested.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924031918/0001104659-24-031918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924031918/tm248252d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-031918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer